BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma
Authors
Keywords
-
Journal
Hematology-American Society of Hematology Education Program
Volume 2014, Issue 1, Pages 125-134
Publisher
American Society of Hematology
Online
2014-11-25
DOI
10.1182/asheducation-2014.1.125
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
- (2014) S. Stilgenbauer et al. BLOOD
- Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib
- (2014) D. Wodarz et al. BLOOD
- Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
- (2014) S. P. Treon et al. BLOOD
- Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
- (2014) S. E. M. Herman et al. BLOOD
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
- (2014) I. W. Flinn et al. BLOOD
- Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
- (2014) H. E. Kohrt et al. BLOOD
- A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2014) B. S. Kahl et al. BLOOD
- Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
- (2014) J. A. Woyach et al. BLOOD
- Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia
- (2014) Claire V. Hutchinson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Spleen Tyrosine Kinase Inhibitors for Rheumatoid Arthritis: Where Are We Now?
- (2014) Ian C. Scott et al. DRUGS
- CD49d Is the Strongest Flow Cytometry–Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia
- (2014) Pietro Bulian et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Waldenström macroglobulinemia: from biology to treatment
- (2014) Ilyas Sahin et al. Expert Review of Hematology
- P110 -mediated constitutive PI3K signaling limits the efficacy of p110 -selective inhibition in mantle cell lymphoma, particularly with multiple relapse
- (2013) S. Iyengar et al. BLOOD
- A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
- (2013) G. Yang et al. BLOOD
- Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
- (2013) J. A. Woyach et al. BLOOD
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- (2013) Susan O'Brien et al. LANCET ONCOLOGY
- BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
- (2013) S Cheng et al. LEUKEMIA
- Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia
- (2013) S E M Herman et al. LEUKEMIA
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
- (2013) Jan A. Burger et al. LEUKEMIA & LYMPHOMA
- Targeting pathological B cell receptor signalling in lymphoid malignancies
- (2013) Ryan M. Young et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- B-cell receptor signaling as a driver of lymphoma development and evolution
- (2013) Carsten U. Niemann et al. SEMINARS IN CANCER BIOLOGY
- How the microenvironment wires the natural history of chronic lymphocytic leukemia
- (2013) Federico Caligaris-Cappio et al. SEMINARS IN CANCER BIOLOGY
- B cell receptor signaling in chronic lymphocytic leukemia
- (2013) Jan A. Burger et al. TRENDS IN IMMUNOLOGY
- PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
- (2012) Lomon So et al. BIOCHEMICAL JOURNAL
- Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies
- (2012) A. Agathangelidis et al. BLOOD
- Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
- (2012) A. Wiestner BLOOD
- The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia
- (2012) C. Le Roy et al. BLOOD
- The B-cell receptor signaling pathway as a therapeutic target in CLL
- (2012) J. A. Woyach et al. BLOOD
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
- (2012) Joseph J. Buggy et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
- (2012) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
- (2012) Marcus Dühren-von Minden et al. NATURE
- MYD88 L265P Somatic Mutation in IgM MGUS
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
- (2012) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia
- (2011) A. Paterson et al. BLOOD
- A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
- (2011) D. Bagnara et al. BLOOD
- The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
- (2011) S. Ponader et al. BLOOD
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- B-cell receptor signaling in chronic lymphocytic leukemia
- (2011) F. K. Stevenson et al. BLOOD
- Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation
- (2011) GV Baracho et al. CURRENT OPINION IN IMMUNOLOGY
- Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man
- (2011) Rudi W Hendriks et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1
- (2011) Yair Herishanu et al. LEUKEMIA & LYMPHOMA
- Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia
- (2011) J. A. Burger Hematology-American Society of Hematology Education Program
- The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia
- (2010) Y. Herishanu et al. BLOOD
- CCL3 (MIP-1 ) plasma levels and the risk for disease progression in chronic lymphocytic leukemia
- (2010) M. Sivina et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
- (2010) M. Buchner et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Chemoimmunotherapy of chronic lymphocytic leukemia
- (2010) Constantine S. Tam et al. Nature Reviews Clinical Oncology
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
- (2009) M. P. Quiroga et al. BLOOD
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation
- (2009) S. Deaglio et al. HAEMATOLOGICA
- The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
- (2008) M. Luqman et al. BLOOD
- Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy
- (2008) M. Muzio et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Expression and function of toll like receptors in chronic lymphocytic leukaemia cells
- (2008) Marta Muzio et al. BRITISH JOURNAL OF HAEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation